A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma

NCT05015621 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Neuroendocrine Carcinoma

Interventions

DRUG: Surufatinib plus Toripalimab
DRUG: 5-fluorouracil, Calcium folinate and Irinotecan

Sponsor

Hutchison Medipharma Limited